Akira Takahara

Summary

Country: Japan

Publications

  1. ncbi request reprint Neuronal Ca2+ channel blocking action of an antihypertensive drug, cilnidipine, in IMR-32 human neuroblastoma cells
    Akira Takahara
    Pharmaceutical Research Laboratories, Pharmaceuticals Company, Ajinomoto Co, Inc, 1 1 Suzuki cho, Kawasaki ku, Kawasaki 210 8681, Japan
    Hypertens Res 26:743-7. 2003
  2. ncbi request reprint Discovery, structure-activity relationship study, and oral analgesic efficacy of cyproheptadine derivatives possessing N-type calcium channel inhibitory activity
    Takashi Yamamoto
    Pharmaceutical Research Laboratory, Ajinomoto Company Inc, 1 1, Suzuki cho, Kawasaki ku, Kawasaki shi, Japan
    Bioorg Med Chem 14:5333-9. 2006
  3. doi request reprint Discovery and evaluation of selective N-type calcium channel blockers: 6-unsubstituted-1,4-dihydropyridine-5-carboxylic acid derivatives
    Takashi Yamamoto
    Exploratory Research Laboratories, Ajinomoto Pharmaceuticals Co Ltd, Kawasaki ku, Kawasaki shi, Kanagawa, Japan
    Bioorg Med Chem Lett 22:3639-42. 2012
  4. doi request reprint Asymmetric synthesis and biological evaluations of (+)- and (-)-6-dimethoxymethyl-1,4-dihydropyridine-3-carboxylic acid derivatives blocking N-type calcium channels
    Takashi Yamamoto
    Exploratory Research Laboratories, Ajinomoto Pharmaceuticals Co, Ltd, 1 1, Suzuki cho, Kawasaki ku, Kawasaki shi, Kanagawa, Japan
    Bioorg Med Chem Lett 21:3317-9. 2011
  5. ncbi request reprint Effects of L/N-type calcium channel antagonist, cilnidipine on progressive renal injuries in Dahl salt-sensitive rats
    Tomoyuki Konda
    Pharmaceutical Research Laboratories, Ajinomoto Co, Inc, Kawasaki, Kanagawa, Japan
    Biol Pharm Bull 29:933-7. 2006
  6. doi request reprint The structure-activity relationship study on 2-, 5-, and 6-position of the water soluble 1,4-dihydropyridine derivatives blocking N-type calcium channels
    Takashi Yamamoto
    Pharmaceutical Research Laboratory, Ajinomoto Company Inc, 1 1, Suzuki cho, Kawasaki ku, Kawasaki shi, Japan
    Bioorg Med Chem Lett 18:4813-6. 2008
  7. ncbi request reprint The N- and L-type calcium channel blocker cilnidipine suppresses renal injury in dahl rats fed a high-sucrose diet, an experimental model of metabolic syndrome
    Tomoyuki Konda
    Pharmaceutical Research Laboratories, Ajinomoto Co Inc, Kawasaki, Japan
    Nephron Physiol 101:p1-13. 2005
  8. ncbi request reprint Structure-activity relationship study of 1,4-dihydropyridine derivatives blocking N-type calcium channels
    Takashi Yamamoto
    Pharmaceutical Research Laboratory, Ajinomoto Company Inc, Kawasaki ku, Kawasaki shi, Japan
    Bioorg Med Chem Lett 16:798-802. 2006
  9. ncbi request reprint Neuroprotective effects of a dual L/N-type Ca(2+) channel blocker cilnidipine in the rat focal brain ischemia model
    Akira Takahara
    Pharmaceutical Research Laboratories, Pharmaceuticals Company, Ajinomoto Co Inc, 1 1 Suzuki cho, Kawasaki ku, Kawaski 210 8681, Japan
    Biol Pharm Bull 27:1388-91. 2004
  10. ncbi request reprint Cardiovascular effects of an L/N-type Ca2+ channel blocker cilnidipine assessed in the chronic atrioventricular conduction block dogs
    Akira Takahara
    Pharmaceutical Research Laboratories, Pharmaceuticals Company, Ajinomoto Co, Inc, 1 1 Suzuki cho, Kawasaki ku, Kawasaki 210 8681, Japan
    J Pharmacol Sci 96:219-23. 2004

Collaborators

Detail Information

Publications17

  1. ncbi request reprint Neuronal Ca2+ channel blocking action of an antihypertensive drug, cilnidipine, in IMR-32 human neuroblastoma cells
    Akira Takahara
    Pharmaceutical Research Laboratories, Pharmaceuticals Company, Ajinomoto Co, Inc, 1 1 Suzuki cho, Kawasaki ku, Kawasaki 210 8681, Japan
    Hypertens Res 26:743-7. 2003
    ....
  2. ncbi request reprint Discovery, structure-activity relationship study, and oral analgesic efficacy of cyproheptadine derivatives possessing N-type calcium channel inhibitory activity
    Takashi Yamamoto
    Pharmaceutical Research Laboratory, Ajinomoto Company Inc, 1 1, Suzuki cho, Kawasaki ku, Kawasaki shi, Japan
    Bioorg Med Chem 14:5333-9. 2006
    ..13 showed an oral analgesic activity in rat formalin-induced pain model...
  3. doi request reprint Discovery and evaluation of selective N-type calcium channel blockers: 6-unsubstituted-1,4-dihydropyridine-5-carboxylic acid derivatives
    Takashi Yamamoto
    Exploratory Research Laboratories, Ajinomoto Pharmaceuticals Co Ltd, Kawasaki ku, Kawasaki shi, Kanagawa, Japan
    Bioorg Med Chem Lett 22:3639-42. 2012
    ..Among the tested compounds, (+)-4-(3,5-dichloro-4-methoxy-phenyl)-1,4-dihydro-pyridine-3,5-dicarboxylic acid 3-cinnamyl ester was found to be an effective and selective N-type calcium channel blocker with oral analgesic potential...
  4. doi request reprint Asymmetric synthesis and biological evaluations of (+)- and (-)-6-dimethoxymethyl-1,4-dihydropyridine-3-carboxylic acid derivatives blocking N-type calcium channels
    Takashi Yamamoto
    Exploratory Research Laboratories, Ajinomoto Pharmaceuticals Co, Ltd, 1 1, Suzuki cho, Kawasaki ku, Kawasaki shi, Kanagawa, Japan
    Bioorg Med Chem Lett 21:3317-9. 2011
    ....
  5. ncbi request reprint Effects of L/N-type calcium channel antagonist, cilnidipine on progressive renal injuries in Dahl salt-sensitive rats
    Tomoyuki Konda
    Pharmaceutical Research Laboratories, Ajinomoto Co, Inc, Kawasaki, Kanagawa, Japan
    Biol Pharm Bull 29:933-7. 2006
    ....
  6. doi request reprint The structure-activity relationship study on 2-, 5-, and 6-position of the water soluble 1,4-dihydropyridine derivatives blocking N-type calcium channels
    Takashi Yamamoto
    Pharmaceutical Research Laboratory, Ajinomoto Company Inc, 1 1, Suzuki cho, Kawasaki ku, Kawasaki shi, Japan
    Bioorg Med Chem Lett 18:4813-6. 2008
    ..As a consequence of the optimization, 6-dimethylacetal derivative 7 was found to have an effective inhibitory activity against N-type calcium channels with more than 170-fold lower activity for L-type channel compared to that of APJ2708...
  7. ncbi request reprint The N- and L-type calcium channel blocker cilnidipine suppresses renal injury in dahl rats fed a high-sucrose diet, an experimental model of metabolic syndrome
    Tomoyuki Konda
    Pharmaceutical Research Laboratories, Ajinomoto Co Inc, Kawasaki, Japan
    Nephron Physiol 101:p1-13. 2005
    ....
  8. ncbi request reprint Structure-activity relationship study of 1,4-dihydropyridine derivatives blocking N-type calcium channels
    Takashi Yamamoto
    Pharmaceutical Research Laboratory, Ajinomoto Company Inc, Kawasaki ku, Kawasaki shi, Japan
    Bioorg Med Chem Lett 16:798-802. 2006
    ....
  9. ncbi request reprint Neuroprotective effects of a dual L/N-type Ca(2+) channel blocker cilnidipine in the rat focal brain ischemia model
    Akira Takahara
    Pharmaceutical Research Laboratories, Pharmaceuticals Company, Ajinomoto Co Inc, 1 1 Suzuki cho, Kawasaki ku, Kawaski 210 8681, Japan
    Biol Pharm Bull 27:1388-91. 2004
    ..Thus, treatment of hypertension with cilnidipine may prevent severe consequences after brain attack...
  10. ncbi request reprint Cardiovascular effects of an L/N-type Ca2+ channel blocker cilnidipine assessed in the chronic atrioventricular conduction block dogs
    Akira Takahara
    Pharmaceutical Research Laboratories, Pharmaceuticals Company, Ajinomoto Co, Inc, 1 1 Suzuki cho, Kawasaki ku, Kawasaki 210 8681, Japan
    J Pharmacol Sci 96:219-23. 2004
    ..These results suggest that cilnidipine not only decreases the blood pressure, but also decreases the sinus automaticity in the in vivo hypertensive condition with increased adrenergic tones...
  11. ncbi request reprint Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke
    Takashi Yamamoto
    Pharmaceutical Research Lab, Pharmaceutical Company, Ajinomoto Co, Inc Kanagawa, 210 8681, Japan
    Curr Top Med Chem 9:377-95. 2009
    ..The pharmacological advantages of N-type calcium channel blockers in these pathological states are also described...
  12. ncbi request reprint Antisympathetic and hemodynamic property of a dual L/N-type Ca(2+) channel blocker cilnidipine in rats
    Akira Takahara
    Pharmaceutical Research Laboratories, Ajinomoto Co, Inc, 1 1 Suzuki cho, Kawasaki ku, Kawasaki 210 8681, Japan
    Eur J Pharmacol 434:43-7. 2002
    ..The antisympathetic activity of cilnidipine is not excessive for an antihypertensive drug in comparison with that of omega-conotoxin MVIIA...
  13. ncbi request reprint Cardiac Ca(2+) channel-blocking effects of the cyproheptadine derivative AH-1058 in isolated guinea pig cardiomyocytes
    Hideki Dohmoto
    Pharmaceutical Research Laboratories, Pharmaceuticals Company, Ajinomoto Co, Inc, Kawasaki, Japan
    J Pharmacol Sci 91:163-6. 2003
    ..These results suggest that the introduction of the cinnamil structure to cyproheptadine can generate a potent L-type Ca(2+) channel-blocking compound as potent as verapamil...
  14. ncbi request reprint Cardiac effects of L/N-type Ca2+ channel blocker cilnidipine in anesthetized dogs
    Akira Takahara
    Department of Pharmacology, Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, Chuo, Yamanashi 409 3898, Japan
    Eur J Pharmacol 565:166-70. 2007
    ..These results suggest that clinically relevant doses of cilnidipine can directly attenuate the sympathetic tone...
  15. doi request reprint Intracellular mechanisms and receptor types for endothelin-1-induced positive and negative inotropy in mouse ventricular myocardium
    Iyuki Namekata
    Department of Pharmacology, Toho University Faculty of Pharmaceutical Sciences, Miyama 2 2 1 Funabashi, Chiba, 274 8510, Japan
    Naunyn Schmiedebergs Arch Pharmacol 376:385-95. 2008
    ....
  16. ncbi request reprint Species difference in the contribution of T-type calcium current to cardiac pacemaking as revealed by r(-)-efonidipine
    Hikaru Tanaka
    Department of Pharmacology, Toho University Faculty of Pharmaceutical Sciences, Japan
    J Pharmacol Sci 107:99-102. 2008
    ..These results provide the first pharmacological evidence that the contribution of T-type Ca2+ current to cardiac pacemaking differs among experimental animal species...
  17. ncbi request reprint Comparison of the direct negative dromotropic effect of a new calcium channel blocker, cilnidipine, with that of nicardipine
    Atsushi Sugiyama
    Department of Pharmacology, Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, Tamaho cho, Nakakoma gun, Yamanashi, 409 3898, Japan
    Heart Vessels 20:112-5. 2005
    ....